

Lantheus Radiopharmaceutical Pipeline

	CANDIDATE	TARGET	ISOTOPE	INDICATION / DISEASE AREA	PRE-CLINICAL	PHASE I	PHASE II	PHASE III	REGISTRATIONAL
 ONCOLOGY	DIAGNOSTIC	LNTH-2501	SSTR	⁶⁸ Ga	Neuroendocrine Tumors				
		LNTH-2401	GRPR	⁶⁸ Ga	Prostate Cancer				
		LNTH-2503	CCK2R	⁶⁸ Ga	Small Cell Lung Cancer				
		LNTH-1363S	FAP	⁶⁴ Cu	Sarcoma/GI				
		LNTH-2507	Undisc.	⁶⁸ Ga	Pancreatic Ductal Adenocarcinoma				
	THERAPEUTIC	PNT2003†	SSTR	¹⁷⁷ Lu	GEP-NETs				
		LNTH-2403	LRRC15	¹⁷⁷ Lu	Relapsed/Refractory Osteosarcoma				
		LNTH-2503	CCK2R	¹⁷⁷ Lu	Small Cell Lung Cancer				
		LNTH-2402	GRPR	¹⁷⁷ Lu	Metastatic Prostate Cancer				
		LNTH-2507	Undisc.	¹⁷⁷ Lu	Pancreatic Ductal Adenocarcinoma				
 NEUROLOGY	DIAGNOSTIC	NAV-4694 / Flutafuranol	B amyloid	¹⁸ F	Alzheimer's Disease				
		LNTH-2620 / PI-2620	Tau	¹⁸ F	Alzheimer's Disease				
 CARDIOLOGY	DIAGNOSTIC	LNTH-2515 / Florbetaben	Amyloid	¹⁸ F	Cardiac AL Amyloidosis				
		LNTH-2513 / GP-1	GPIIb-IIIa	¹⁸ F	Thromboembolism				

† PNT2003 received tentative FDA approval on March 2, 2026. Final FDA approval has not yet been granted. Final approval is contingent upon resolution of outstanding regulatory and legal matters.

DIAGNOSTIC ■
THERAPEUTIC ■